Trifarotene - Galderma

Drug Profile

Trifarotene - Galderma

Alternative Names: CD-5789

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Galderma
  • Developer Galderma; University of Texas M. D. Anderson Cancer Center
  • Class Antiacnes; Antineoplastics; Benzoic acids; Keratolytics; Pyrrolidines; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ichthyosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris
  • Phase II Ichthyosis
  • No development reported Cutaneous T cell lymphoma

Most Recent Events

  • 14 Nov 2017 Galderma completes a phase III trial in Acne vulgaris (In adolescents, In children, In adults) in USA, Czech Republic, Germany, Hungary, Canada and Puerto Rico (Topical) (EudraCT2016-002860-15) (NCT02566369)
  • 23 Feb 2017 Galderma completes a phase III trial in Acne vulgaris (In children, In adolescents, In adults) in USA, Czech Republic, Germany and Hungary (NCT02189629)
  • 07 Feb 2017 Galderma completes a phase-III trial in Acne vulgaris (In children, In adolescents, In adults) in USA, Czech Republic, Hungary, Poland, Romania, Russia, Spain, Ukraine (NCT02556788)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top